Lantern Pharma Inc. LTRN Archives

MondayJul 28, 2025 9:00 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder and former CEO of Oncoceutics Inc., brings over 20 years of experience in biotechnology leadership and financial markets, with a track record in developing targeted therapies for solid tumors, including HK327M-mutant gliomas. Oncoceutics was acquired by Chimerix Inc. (NASDAQ: CMRX) for $450 million in 2021 and later by Jazz Pharmaceuticals for $935 million in April 2025. Lantern CEO Panna Sharma said Dr. Schalop’s expertise in…

MondayJul 21, 2025 9:40 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern’s RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern’s strategic partnership potential. To view…

TuesdayJul 15, 2025 11:20 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications. To…

MondayJun 30, 2025 1:12 pm

QualityStocksNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent article. “The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC’), triple-negative breast cancer (‘TNBC’), and non-Hodgkin’s lymphoma (‘NHL’)… Starlight Therapeutics extends Lantern’s footprint into…

ThursdayJun 26, 2025 9:45 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population. The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning…

WednesdayJun 11, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations. Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways. With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support…

Site Search

Company Search

Tag: Lantern Pharma Inc. LTRN

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

QualityStocksNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Market Basics

Newsletter Publishers

Public Companies